Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Generated $50.0 million in net revenue from sales of LUMRYZ™ ----2,300 patients on LUMRYZ as of September 30th, including 700 patients that ...